CoChat

Intraneuronal Aβ42 Accumulation in Human Brain

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is characterized by the deposition of senile plaques (SPs) and neurofibrillary tangles (NFTs) in vulnerable brain regions. SPs are composed of aggregated beta-amyloid (Abeta) 40/42(43) peptides. Evidence implicates a central role for Abeta in the pathophysiology of AD. Mutations in betaAPP and presenilin 1 (PS1) lead to elevated secretion of Abeta, especially the more amyloidogenic Abeta42. Immunohistochemical studies have also emphasized the importance of Abeta42 in initiating plaque pathology. Cell biological studies have demonstrated that Abeta is generated intracellularly. Recently, endogenous Abeta42 staining was demonstrated within cultured neurons by confocal immunofluorescence microscopy and within neurons of PS1 mutant transgenic mice. A central question about the role of Abeta in disease concerns whether extracellular Abeta deposition or intracellular Abeta accumulation initiates the disease process. Here we report that human neurons in AD-vulnerable brain regions specifically accumulate gamma-cleaved Abeta42 and suggest that this intraneuronal Abeta42 immunoreactivity appears to precede both NFT and Abeta plaque deposition. This study suggests that intracellular Abeta42 accumulation is an early event in neuronal dysfunction and that preventing intraneuronal Abeta42 aggregation may be an important therapeutic direction for the treatment of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0002-9440(10)64700-1

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Intraneuronal A 𝛃 42 accumulation occurs in AD-vulnerable neurons before the formation of senile plaques. A, Left: Neuronal A 𝛃 42 staining (RU antibody) in the CA1 region of hippocampus derived from a 64-year-old patient with mild (CDR 0.5) cognitive dysfunction. Right: A 𝛃 40 staining from the same CA1 region shows only slight immunoreactivity compared with the more pronounced intracytoplasmic staining seen with A 𝛃 42. Antibody concentrations and time of development were equivalent. Bar = 60 𝛍 m. B, Left: A 𝛃 42 immunoreactivity (RU antibody) in basal forebrain magnocellular neurons. Right: This staining is abolished by A 𝛃 1-42 peptide competition; a blue filter was used to highlight negatively staining neurons. Bar = 60 𝛍 m. C, Left: A 𝛃 42 staining (QCB) in the CA4 region of hippocampus from a neurologically normal 3-year-old patient (control); only faint neuronal staining can be seen ( left ), Bar = 60 𝛍 m. Center: Pronounced CA4 A 𝛃 42 immunoreactivity (QCB) in a 3-year-old with Down's syndrome. The arrow indicates a neuron with intracellular staining. Bar = 40 𝛍 m. Right: A 𝛃 42 staining (QCB) in a 79-year-old without dementia indicates marked A 𝛃 42 intracellular staining in layer II neurons ( arrows ) of the entorhinal cortex. Bar = 100 𝛍 m. D, Left: In this 83-year-old cognitively impaired subject (CDR1), the absence of intranuclear A 𝛃 42 staining is evident in neurons stained for A 𝛃 42 (RU). Early A 𝛃 42 aggregates appear to be present within a neuron marked by an arrow ; the inset provides another example of such seemingly intracellular A 𝛃 42 accumulation in (RU) in a 94-year-old CDR 2 case. Bar = 40 𝛍 m. Center: 'Neuronal' shaped SP ( arrow ) adjacent to a more conventional spherical SP in a 72-year-old subject with advanced AD (RU A 𝛃 42). Bar = 60 𝛍 m. Right: The CA1 region of a 79-year-old cognitively impaired subject (CDR1) demonstrates both intraneuronal A 𝛃 42 immunoreactivity (QCB) and apparent extraneuronal diffuse plaque-like staining ( arrow ) adjacent to a few neurons. Bar = 40 𝛍 m.
Figure 1 Intraneuronal A 𝛃 42 accumulation occurs in AD-vulnerable neurons before the formation of senile plaques. A, Left: Neuronal A 𝛃 42 staining (RU antibody) in the CA1 region of hippocampus derived from a 64-year-old patient with mild (CDR 0.5) cognitive dysfunction. Right: A 𝛃 40 staining from the same CA1 region shows only slight immunoreactivity compared with the more pronounced intracytoplasmic staining seen with A 𝛃 42. Antibody concentrations and time of development were equivalent. Bar = 60 𝛍 m. B, Left: A 𝛃 42 immunoreactivity (RU antibody) in basal forebrain magnocellular neurons. Right: This staining is abolished by A 𝛃 1-42 peptide competition; a blue filter was used to highlight negatively staining neurons. Bar = 60 𝛍 m. C, Left: A 𝛃 42 staining (QCB) in the CA4 region of hippocampus from a neurologically normal 3-year-old patient (control); only faint neuronal staining can be seen ( left ), Bar = 60 𝛍 m. Center: Pronounced CA4 A 𝛃 42 immunoreactivity (QCB) in a 3-year-old with Down's syndrome. The arrow indicates a neuron with intracellular staining. Bar = 40 𝛍 m. Right: A 𝛃 42 staining (QCB) in a 79-year-old without dementia indicates marked A 𝛃 42 intracellular staining in layer II neurons ( arrows ) of the entorhinal cortex. Bar = 100 𝛍 m. D, Left: In this 83-year-old cognitively impaired subject (CDR1), the absence of intranuclear A 𝛃 42 staining is evident in neurons stained for A 𝛃 42 (RU). Early A 𝛃 42 aggregates appear to be present within a neuron marked by an arrow ; the inset provides another example of such seemingly intracellular A 𝛃 42 accumulation in (RU) in a 94-year-old CDR 2 case. Bar = 40 𝛍 m. Center: 'Neuronal' shaped SP ( arrow ) adjacent to a more conventional spherical SP in a 72-year-old subject with advanced AD (RU A 𝛃 42). Bar = 60 𝛍 m. Right: The CA1 region of a 79-year-old cognitively impaired subject (CDR1) demonstrates both intraneuronal A 𝛃 42 immunoreactivity (QCB) and apparent extraneuronal diffuse plaque-like staining ( arrow ) adjacent to a few neurons. Bar = 40 𝛍 m.CC-BY-NC-ND · From the PDF
Figure 2 A: Intraneuronal A 𝛃 42 immunoreactivity (QCB) in layer II (islands of Calleja) of the entorhinal cortex ( arrow ) in a 90-year-old CDR1 patient, compared with the absence of staining ( arrow ) in an 83-year-old CDR2 patient; A 𝛃 42 immunoreactive plaques can be seen above. In the CDR 2 patient, note the emergence of A 𝛃 40 SPs. Bar = 100 𝛍 m. B: Abundant A 𝛃 42 immunoreactivity (RU) compared with only occasional AT8 staining for hyperphosphorylated tau in the CA1 region of a 94-year-old patient (CDR 2). Bar = 60 𝛍 m. C: Adjacent sections of CA4 (below) and dentate gyrus (above) immunostained with antibodies to A 𝛃 40, A 𝛃 42 (QCB), and apoE in an 83-year-old cognitively impaired patient (CDR 2). Noticeable intraneuronal apoE staining is evident ( inset , enlarged × 5). Bar = 100 𝛍 m.
Figure 2 A: Intraneuronal A 𝛃 42 immunoreactivity (QCB) in layer II (islands of Calleja) of the entorhinal cortex ( arrow ) in a 90-year-old CDR1 patient, compared with the absence of staining ( arrow ) in an 83-year-old CDR2 patient; A 𝛃 42 immunoreactive plaques can be seen above. In the CDR 2 patient, note the emergence of A 𝛃 40 SPs. Bar = 100 𝛍 m. B: Abundant A 𝛃 42 immunoreactivity (RU) compared with only occasional AT8 staining for hyperphosphorylated tau in the CA1 region of a 94-year-old patient (CDR 2). Bar = 60 𝛍 m. C: Adjacent sections of CA4 (below) and dentate gyrus (above) immunostained with antibodies to A 𝛃 40, A 𝛃 42 (QCB), and apoE in an 83-year-old cognitively impaired patient (CDR 2). Noticeable intraneuronal apoE staining is evident ( inset , enlarged × 5). Bar = 100 𝛍 m.CC-BY-NC-ND · From the PDF
Figure 3 Metabolic labeling and immunoprecipitation of intraneuronal A 𝛃 40 and A 𝛃 42. A: Primary mouse neuronal cultures. Top: IP of conditioned medium indicates significantly lower secretion of A 𝛃 42 compared with A 𝛃 40. Bottom: Comparable amounts of A 𝛃 40 and A 𝛃 42 species in neuronal cell lysate. B: A 𝛃 40 and A 𝛃 42 species in sucrose density gradients from neuroblastoma cells harboring the 𝚫 10eFAD PS1 mutation. A 𝛃 1-40, A 𝛃 x-40, and A 𝛃 1-42 species predominate in the Golgi-enriched fraction, whereas A 𝛃 x-42 predominates in the ER-enriched fraction.
Figure 3 Metabolic labeling and immunoprecipitation of intraneuronal A 𝛃 40 and A 𝛃 42. A: Primary mouse neuronal cultures. Top: IP of conditioned medium indicates significantly lower secretion of A 𝛃 42 compared with A 𝛃 40. Bottom: Comparable amounts of A 𝛃 40 and A 𝛃 42 species in neuronal cell lysate. B: A 𝛃 40 and A 𝛃 42 species in sucrose density gradients from neuroblastoma cells harboring the 𝚫 10eFAD PS1 mutation. A 𝛃 1-40, A 𝛃 x-40, and A 𝛃 1-42 species predominate in the Golgi-enriched fraction, whereas A 𝛃 x-42 predominates in the ER-enriched fraction.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 998

Metadata

Authors
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., Greengard, P., & Relkin, N. R.
Affiliations
  • Cornell University (US)
  • Rockefeller University (US)
  • Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Gouras, Gunnar K.
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2000-01
Volume
156
Issue
1
Pages
15-20
ISSN
0002-9440 (ISSN-L)
OpenAlex
W2048975745
Cited by
991
References
29
Citations by year
2026: 16 · 2025: 30 · 2024: 26 · 2023: 25 · 2022: 37 · 2021: 32 · 2020: 43 · 2019: 39 · 2018: 34 · 2017: 37 · 2016: 26 · 2015: 46 · 2014: 33 · 2013: 39 · 2012: 43
FWCI
24.26
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal Of Pathology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Alzheimer's Association
  • American Health Assistance Foundation
  • U.S. Public Health Service (AG09464, AG05138, NS02037)
  • Ellison Medical Foundation
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, amyloid-beta 42, amyloid plaques, neurofibrillary tangles, presenilin 1 mutations, amyloid precursor protein, pathogenesis
MeSH terms
Adult, Aged, Aged, 80 and over, Brain, Cadaver, Cognition Disorders, Dementia, Down Syndrome, Humans, Immunohistochemistry, Infant, Middle Aged, Neurons, Peptide Fragments, Reference Values, Amyloid beta-Peptides, Neurofibrillary Tangles, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intraneuronal Aβ42 Accumulation in Human Brain. https://app.cochat.ai/papers/10.1016/s0002-9440(10)64700-1
The paper
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., Greengard, P., & Relkin, N. R. (2000). Intraneuronal Aβ42 Accumulation in Human Brain. The American Journal of Pathology. https://doi.org/10.1016/s0002-9440(10)64700-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.